Check Point (CHKP – Research Report) received a Hold rating and a $207.00 price target from Goldman Sachs analyst Gabriela Borges yesterday.

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

HIF1α identified as key regulator that induces cancer-killing ability of hypoxic T cells, playing a role in ICB resistance.

Loss of the Y chromosome (LOY) in men, a dynamic mutation linked to aging, impairs immune function and increases risks of ...

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments.

Among the most profound results presented at the 2024 European Society for Medical Oncology Congress were the 10-year data ...

Check Point Software Technologies Ltd. (NASDAQ:CHKP – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...